Advertisement
Mayo Clinic Proceedings Home

Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test

      Abstract

      Objective

      To evaluate the effect of aspirin and nonaspirin antiplatelet agents (NAAAs) on the performance of the fecal immunochemical test (FIT).

      Participants and Methods

      We performed a post hoc analysis of results from a clinical trial that involved 28,696 asymptomatic average-risk men and women aged 50 to 69 years invited to participate in a colorectal cancer screening program with FIT between November 1, 2008, and June 31, 2011.

      Results

      The test was returned by 6390 individuals (22.3%), of whom 5821 (91.1%) reported not using antiplatelet drugs (nonusers group) and 569 (8.9%) reported using these drugs at the time of testing (users group). The FIT result was positive in 48 of 569 users (8.4%) and 365 of 5821 nonusers (6.3%) (P=.05). A positive FIT result was found in 7.3% (28/384) of aspirin users, 7.1% (10/140) of NAAA users, and 22.2% (10/45) of those undergoing dual antiplatelet therapy (DAPT) (aspirin plus an NAAA). The DAPT subgroup had a significantly higher positive FIT rate than the nonuser group (odds ratio, 3.5; 95% CI, 1.7-7.3; P<.05). The positive predictive value (PPV) for advanced neoplasia (AN) in nonusers was 50.4% vs 50.0% in users (P = .40). The PPV for AN was 57.0% in aspirin users, 30.0% in NAAA users, and 50.0% in DAPT users, without statistically significant differences between the user and nonuser groups.

      Conclusion

      The use of DAPT increased the rate of positive FIT results. Use of aspirin, NAAAs, or both did not modify the PPV for AN in this population-based colorectal screening program.

      Trial Registration

      Abbreviations and Acronyms:

      AA (advanced adenoma), AN (advanced neoplasia), CRC (colorectal cancer), DAPT (dual antiplatelet therapy), FIT (fecal immunochemical test), NAAA (nonaspirin antiplatelet agent), NAN (nonadvanced neoplasia), PPV (positive predictive value)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Shin H.R.
        • Bray F.
        • Forman D.
        • Mathers C.
        • Parkin D.M.
        Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
        Int J Cancer. 2010; 127: 2893-2917
        • Levin B.
        • Lieberman D.A.
        • McFarland B.
        • et al.
        Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
        Gastroenterology. 2008; 134: 1570-1595
        • Mandel J.S.
        • Church T.R.
        • Bond J.H.
        • et al.
        The effect of fecal occult-blood screening on the incidence of colorectal cancer.
        N Engl J Med. 2000; 343: 1603-1607
        • Hewitson P.
        • Glasziou P.
        • Watson E.
        • Towler B.
        • Irwig L.
        Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update.
        Am J Gastroenterol. 2008; 103: 1541-1549
        • Atkin W.S.
        • Edwards R.
        • Kralj-Hans I.
        • et al.
        Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.
        Lancet. 2010; 375: 1624-1633
        • Heitman S.J.
        • Hilsden R.J.
        • Au F.
        • Dowden S.
        • Manns B.J.
        Colorectal cancer screening for average-risk North Americans: an economic evaluation.
        PLoS Med. 2010; 7: 1-13
        • Sawhney M.S.
        • McDougall H.
        • Nelson D.B.
        • Bond J.H.
        Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs.
        Dig Dis Sci. 2010; 55: 1637-1642
        • Mandelli G.
        • Radaelli F.
        • Paggi S.
        • et al.
        Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study.
        Eur J Gastroenterol Hepatol. 2011; 23: 323-326
        • Levi Z.
        • Rozen P.
        • Hazazi R.
        • et al.
        Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs and anticoagulants.
        Am J Gastroenterol. 2009; 104: 933-938
        • Quintero E.
        • Castells A.
        • Bujanda L.
        • et al.
        Colonoscopy versus fecal immunochemical test in colorectal cancer screening.
        N Engl J Med. 2012; 366: 697-706
        • Vilkin A.
        • Rozen P.
        • Levi Z.
        • et al.
        Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
        Am J Gastroenterol. 2005; 100: 2519-2525
        • O'Connell J.B.
        • Maggard M.A.
        • Ko C.Y.
        Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.
        J Natl Cancer Inst. 2004; 96: 1420-1425
        • Jover R.
        • Herráiz M.
        • Alarcón O.
        • et al.
        • Spanish Society of Gastroenterology; Spanish Society of Gastrointestinal Endoscopy Working Group
        Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening.
        Endoscopy. 2012; 44: 444-451
        • Gullov A.L.
        • Koefoed B.G.
        • Petersen P.
        Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study.
        Arch Intern Med. 1999; 159: 1322-1328
        • Sharma V.K.
        • Corder F.A.
        • Fancher J.
        • Howden C.W.
        Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
        Am J Gastroenterol. 2000; 95: 3629-3632
        • Brenner H.
        • Tao S.
        • Haug U.
        Low-dose aspirin use and performance of immunochemical fecal occult blood test.
        JAMA. 2010; 304: 2513-2520
        • Kahi C.J.
        • Rex D.K.
        • Imperiale T.F.
        Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature.
        Gastroenterology. 2008; 135: 380-399
        • Park D.I.
        • Ryu S.
        • Kim Y.
        • et al.
        Comparison guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
        Am J Gastroenterol. 2010; 105: 2017-2025
        • Hernández V.
        • Cubiella J.
        • Gónzalez-Mao C.
        • et al.
        Diagnostic accuracy of the fecal immunochemical test (FIT) to screen for colorectal cancer and advanced neoplasia in individuals with intermediate risk.
        Gastroenterol Hepatol. 2012; 35: 144-145
        • Nakama H.
        • Kamijo N.
        • Fujimori K.
        • et al.
        Diagnostic accuracy of immunochemical faecal occult blood test for gastric cancer.
        J Med Screen. 1996; 3: 113-114
        • Nakama H.
        • Kamijo N.
        • Fattah A.S.
        • Zhang B.
        Immunologic detection of fecal occult blood from upper digestive tract diseases.
        Hepatogastroenterology. 1998; 45: 752-754
        • Nakama H.
        • Zhang B.
        Immunochemical fecal occult blood test is inadequate for screening test of stomach cancer.
        Dig Dis Sci. 2000; 45: 2195-2198
        • van Rossum L.G.
        • van Rijn A.F.
        • Laheij R.J.
        • et al.
        Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in screening population.
        Gastroenterology. 2008; 135: 82-90
        • Allison J.E.
        • Tekawa I.S.
        • Ransom L.J.
        • et al.
        A comparison of fecal occult blood tests for colorectal cancer screening.
        N Engl J Med. 1996; 334: 155-159
        • Blacker D.J.
        • Wijdicks E.F.
        • McClelland R.L.
        Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy.
        Neurology. 2003; 61: 964-968
        • Levin B.
        • Lieberman D.A.
        • McFarland B.
        • et al.
        Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: joint guidelines from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
        Gastroenterology. 2008; 134: 1570-1595
        • Lanas A.
        • García Rodriguez L.A.
        • Arroyo M.T.
        • et al.
        Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
        Gut. 2006; 55: 1731-1738
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K.
        • Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Diener H.-C.
        • Bogousslavsky J.
        • Brass L.M.
        • et al.
        Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients: randomised, double-blind, placebo-controlled trial.
        Lancet. 2004; 364: 331-337
        • Chan A.O.
        • Jim M.H.
        • Lam K.F.
        • et al.
        Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease.
        JAMA. 2007; 298: 1412-1419